ICPT
Intercept Pharmaceuticals, Inc.
19.00
USD
This page is just a preview of the data found in TrendSpider’s full version
Intercept Pharmaceuticals, Inc. stock is up 0.21% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 11 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 8 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 06 Oct 14:35 | 19 Jan, 2024 | 17.50 | 2043 | ||
| 09 Oct 14:51 | 15 Mar, 2024 | 15.00 | 76 | ||
| 13 Oct 19:06 | 17 Nov, 2023 | 20.00 | 6949 | ||
| 13 Oct 19:29 | 15 Dec, 2023 | 15.00 | 1663 | ||
| 20 Oct 19:55 | 15 Dec, 2023 | 15.00 | 1673 | ||
| 27 Oct 14:26 | 19 Jan, 2024 | 10.00 | 265 | ||
| 02 Nov 18:30 | 15 Mar, 2024 | 17.50 | 640 | ||
| 02 Nov 18:30 | 15 Mar, 2024 | 17.50 | 640 |
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.
